Ravi Parikh, MD, MPP, discusses the future of oncology practice, including real-world data, patient engagement, emerging technologies, and policy priorities shaping cancer care.
|Articles|October 9, 2015
Dr. Baumann on Hypoxia-Specific PET Imaging in Head and Neck Cancer
Author(s)Michael Baumann, MD
Michael Baumann, MD, Professor of Radiation Oncology, Director University of Dresden Cancer Center in Dresden, Germany discusses the DDFMISO-trial, which investigated hypoxia-specific PET imaging during radio-chemotherapy for locally advanced head-and-neck cancer.
Advertisement
Michael Baumann, MD, Professor of Radiation Oncology, Director University of Dresden Cancer Center in Dresden, Germany discusses the DDFMISO-trial, which investigated hypoxia-specific PET imaging during radio-chemotherapy for locally advanced head-and-neck cancer.
Advertisement
Related to this article
Renuka Iyer, MD, discusses clear documentation for AI ambient scribes and why multidisciplinary tumor boards remain essential in neuroendocrine tumor care.
Aman Chauhan, MD, reviews DAREON-7 data on obrixtamig plus chemotherapy in DLL3-positive neuroendocrine carcinoma, including response rates by DLL3 level.
Jacob Sands, MD, of Dana-Farber Cancer Institute, discusses survival gains, durability, and safety of tarlatamab plus durvalumab in the phase 3 DeLLphi-305 trial.
Renuka Iyer, MD, explains how NCCN is digitizing its guidelines with structured data to support AI tools, prior authorization, and point-of-care access.
Arvind Dasari, MD, MS, reviews key advances in neuroendocrine tumors, including new PRRT options, alpha emitters, cabozantinib, and clinical trials.
Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.
Nikolaos Trikalinos, MD, reviews CABINET data showing cabozantinib improved PFS in functional and nonfunctional NETs without added grade 3 toxicity.
Advertisement
Advertisement
Trending on Targeted Onc
1
Survey Highlights NMIBC Care Challenges Among US Military Service, Veterans
2
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
3
New ACS Guidelines Push for Earlier Prostate Cancer Screening
4
Temab-A Shows Promising Survival in Pretreated Nonsquamous NSCLC
5